Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)46
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients19
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant17
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients16
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities15
Initial real-world experience with ribociclib in advanced breast cancer14
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies14
Pharmacists’ practices and views regarding management of sexual health in patients with cancer14
Identifying health disparities in lenalidomide access14
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma14
Evaluation of hepatotoxicity due to conditioning regimens in beta thalassemia major and aplastic anemia patients undergoing bone marrow transplantation14
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”14
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors12
Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review12
Exploring the potential relationship between antineoplastic agents and their association with stomatitis and oral candidiasis in cancer patients12
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer12
0.076771974563599